Year-end Sale % OFF 
Abstract
SCC244 is a novel potent and highly selective c-MET inhibitor, which displayed high antitumor activity and desirable pharmacokinetic (PK) profile in preclinical models. This first-in-human phase I study was designed to evaluate the safety, PK, and preliminary efficacy of SCC244. Here, we reported the results from phase Ia part of the study.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
